Fox Chase Cancer Center News

PHILADELPHIA (February 25, 2025) — Erin K. Tagai, PhD, MPH, an Assistant Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center, has received a grant from the Prevent Cancer Foundation to fund development of a ChatBot for patients receiving genetic testing results.

PHILADELPHIA (February 24, 2025) — Starting treatment within 60 days of initial evaluation significantly improves survival rates for rectal cancer patients, according to a study released today by researchers at Fox Chase Cancer Center and Temple Health.

PHILADELPHIA (February 21, 2025) — Fox Chase Cancer Center’s Hossein Borghaei, DO, MS, Elizabeth Plimack, MD, MS, and Lorenzo Galluzzi, PhD, have been named to the 2024 list of Highly Cited Researchers by Clarivate, a leading global provider of transformative intelligence.

PHILADELPHIA (February 18, 2025)—Fox Chase Cancer Center and Temple Health are pleased to announce the hiring of Alyssa R. Goldbach, DO, as an Assistant Professor for Breast Imaging in the Department of Diagnostic Imaging.

PHILADELPHIA (February 17, 2025) — Fox Chase Cancer Center’s Cancer Epigenetics Institute (CEI) will hold its fifth annual free hybrid Cancer Epigenetics Symposium at the Franklin Institute in Philadelphia on Thursday, March 6. The annual event welcomes researchers and scientists to share their work and learn more about the latest discoveries that will bring epigenetics to the forefront of patient care.

PHILADELPHIA (February 17, 2025) — Fox Chase Cancer Center is proud to announce the hiring of Jason A. Damsker, MD, FACP, as a Professor in the Department of Hematology/Oncology.

PHILADELPHIA (February 17, 2025) — Many large corporations have used a four-day workweek to attract and retain talent, but does this model work for nurse managers? A new paper by nurse leaders at Fox Chase Cancer Center makes the case that it does.

PHILADELPHIA (February 15, 2025) — A new study presented today by researchers at Fox Chase Cancer Center shows that some patients with metastatic kidney cancer receiving a combination therapy can safely stop or pause treatment after two years if they have a good response.